Olvimulogene nanivacirepvec Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: GL-ONC, GL-ONC1 and GLV-1h68, GLV-1h68, Olvi-Vec

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

Genelux Corporation2

Indications

Cancer2
Non-small Cell Lung Cancer Recurrent1
Metastatic Squamous Non-Small Cell Lung Carcinoma1
Advanced Squamous Non-Small Cell Lung Carcinoma1
Non-small Cell Lung Cancer Stage IV1

Mobile, Alabama1 trial

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

The University of South Alabama, Mitchell Cancer Institute

Phase 3

Bullhead City, Arizona1 trial

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Pioneer Research Center, LLC

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.